Valuation: Day One Biopharmaceuticals, Inc.

Market Cap 2.22B 1.94B 1.83B 1.66B 3.12B 213B 3.13B 21.94B 8.47B 109B 8.36B 8.17B 349B P/E 2024
-12.4x
P/E 2025 -8.96x
Enterprise Value 1.79B 1.56B 1.47B 1.34B 2.5B 171B 2.51B 17.62B 6.8B 87.13B 6.71B 6.56B 280B EV / Sales 2024
5,707,524x
EV / Sales 2025 3,278,601x
Free-Float
94.59%
Yield 2024 *
-
Yield 2025 -
1 day+0.19%
6 months+1.13%
Current year+131.01%
Current year 8.35
Extreme 8.35
21.53
1 year 6.66
Extreme 6.665
21.53
3 years 5.64
Extreme 5.635
21.53
5 years 5.44
Extreme 5.44
28.35
10 years 5.44
Extreme 5.44
28.7
Manager TitleAgeSince
President - 2026-04-22
Director of Finance/CFO 49 2021-01-31
Chief Tech/Sci/R&D Officer - 2024-01-31
Director TitleAgeSince
Director/Board Member - 2026-04-22
Date Insider Type Main position Quantity % Market Cap. Importance
4/23/26 Issuer sale

Director

272,508 0.2638%
4/23/26
Access Industries, Inc. (New York)
TenderCompany 13,756,908 13.3177%
4/23/26 Issuer sale

Chief Technology Officer

854,272 0.8270%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%+208.01%+54.67% 2.22B
+0.04%+2.67%+51.68%+100.28% 1,027B
-0.09%+1.37%+52.36%+67.23% 651B
-0.02%+3.51%+19.54%+73.52% 467B
-1.22%+3.27%+37.02%+36.52% 350B
-0.79%+2.64%+19.18%+24.76% 268B
+0.58%+6.31%+9.69%+14.26% 257B
+1.55%+0.83%+40.38%+47.92% 205B
+0.79%-1.66%-23.80%-57.76% 190B
-0.52%+3.66%+33.72%+98.37% 187B
Average +0.28%+2.27%+44.78%+45.98% 360.43B
Weighted average by Cap. +0.20%+2.62%+35.35%+61.47%

Financials

2024 2025
Net sales 131.16 114.37 107.99 98.07 183.74 12.59K 184.5 1.29K 499.2 6.4K 492.71 481.77 20.59K 158.18 137.93 130.24 118.27 221.59 15.18K 222.51 1.56K 602.04 7.72K 594.21 581.02 24.83K
Net income -95.5M -83.27M -78.63M -71.4M -134M -9.16B -134M -942M -363M -4.66B -359M -351M -14.99B -107M -93.58M -88.37M -80.24M -150M -10.3B -151M -1.06B -408M -5.24B -403M -394M -16.85B
Net Debt -529M -461M -436M -396M -741M -50.77B -744M -5.22B -2.01B -25.81B -1.99B -1.94B -83.06B -438M -382M -361M -328M -614M -42.06B -617M -4.32B -1.67B -21.38B -1.65B -1.61B -68.8B
Logo Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company's commercial product OJEMDA (tovorafenib), is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor that inhibits both monomeric and dimeric RAF kinase. OJEMDA is the only systemic therapy for pLGG that offers once-weekly dosing, with or without food, as a tablet or oral suspension. Its BRAF products, such as vemurafenib and encorafenib, are referred to as type I RAF inhibitors, which only inhibit RAF monomers and are therefore limited to use in BRAF V600-altered tumors. The DAY301 candidate, is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody, or mAb, conjugated with a topoisomerase I inhibitor (exatecan mesylate) via stable and hydrophilic modified valine-alanine (VA) cleavable linker.
Employees
178
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. DAWN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!